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OBJECTIVE—While patients with diabetes suffer from increased infections and a 
higher incidence of cancer due to impaired immune function, details on 
diabetes-induced decrease in immunity are lacking. We assessed how 
immune-mediating peripheral blood mononuclear cells (PBMCs) are affected in 
diabetes. 
RESEARCH DESIGN AND METHODS—We obtained PBMCs from 33 patients with 
type 2 diabetes and 28 healthy volunteers, and investigated their susceptibility to 
apoptosis and functional alteration. 
RESULTS—In a subpopulation of PBMCs, monocytes derived from patients with 
diabetes were more susceptible to apoptosis than monocytes from healthy volunteers. 
Monocytes from patients with diabetes had decreased phagocytotic activity and were 
less responsive to Toll-like receptor (TLR) ligands, although the expression of TLRs did 
not differ significantly between the two groups. Furthermore, monocytes from patients 
with diabetes had a distinctly different gene expression profile compared to monocytes 
from normal volunteers as assessed with DNA microarray analysis. Specifically, 
quantitative real-time detection PCR measurements showed an elevated expression of 
the markers of endoplasmic reticulum (ER) stress in diabetic monocytes, and electron 
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microscopic examination of monocytes revealed morphological alterations in the ER of 
cells derived from patients with diabetes. Consistently, the ER stress inducer 
tunicamycin increased apoptosis of otherwise healthy monocytes and attenuated the 
pro-inflammatory responses to TLR ligands. 
CONCLUSIONS—These data suggest that monocytes comprise a substantially 
impaired subpopulation of PBMCs in patients with diabetes and that ER stress is 
involved in these pathological changes mechanistically. This implies that the affected 














Type 2 diabetes is the most frequent metabolic disease and the leading cause of 
human morbidity and mortality (1, 2). Based on epidemiological data, patients with 
diabetes are immunocompromised and have an increased incidence of infections in the 
respiratory tract, urinary tract, and skin (3–5). The high incidence of colorectal, breast, 
and pancreatic malignancies in patients with diabetes is also considered to be a 
consequence of diabetes-associated defects in immune function (6, 7).  
Although studies on immune cells and circulating cytokines have shed some 
light on this diabetic immunological phenomenon, conflicting results have been 
reported and do not adequately explain the perturbed immune function in patients with 
diabetes. Controversial results concerning the phagocytotic activity of 
polymorphonuclear neutrophils and monocytes are in part due to differences in the 
patients themselves, insufficient numbers in the study populations, or inconsistencies in 
the collection of the cell populations under investigation (8–11). Therefore, further 
studies are needed to explain the decreased immune function of patients with diabetes.  
We previously investigated the gene expression signatures of peripheral blood 
mononuclear cells (PBMCs) in patients with diabetes and observed transcriptional 
expression features that were distinct from those of healthy volunteers (12). 
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Apoptosis-related genes were up-regulated in the PBMCs of patients with diabetes.  
Based on this result, we investigated apoptotic activity and immunological function in 
PBMCs from patients with type 2 diabetes.  
We observed that the CD14+ monocyte fraction was the most affected 
subpopulation of PBMCs from these patients; these cells were especially vulnerable to 
apoptosis compared to other cell subpopulations. We also found that CD14+ monocytes 
demonstrated attenuated phagocytotic activity and deficient Toll-like receptor (TLR) 
signaling, both of which are important for innate immunity (13, 14). Transcriptional 
analysis and electron microscopic examination of monocytes from patients with 
diabetes showed evidence of endoplasmic reticulum (ER) stress, which may underlie 
the functional defects in these cells. Collectively, the data presented herein show that 
CD14+ monocytes are a vulnerable cell population under ER stress in these patients that 







RESERCH DESIGN AND METHODS 
Patients.  
Thirty-three patients with type 2 diabetes (male/female, 15/18; age, 62.0 ± 8.6 
years; HbA1c, 9.2 ± 2.0%) and 28 healthy volunteers (male/female, 15/13; age, 58.2 ± 
10.2 years; HbA1c, 5.4 ± 0.7%) were enrolled consecutively for the apoptosis assay 
(Table 1). The groups were not significantly different in terms of their clinical 
parameters, except for the fasting plasma glucose (FPG) and HbA1c levels. The patients 
with diabetes (n = 16) from whom adequate numbers of monocytes were obtained were 
enrolled for additional experiments along with 17 other patients with diabetes 
(male/female, 8/9; age, 60.5 ± 7.2 years; HbA1c 8.8 ± 1.8) whose clinical profiles fit the 
diabetic profile (Table 1). Informed consent for this study was obtained from all 
subjects. The experimental protocol was carried out in accordance with the Declaration 
of Helsinki. 
 
Isolation of subpopulations of PBMCs and flow cytometric analysis.  
PBMCs were freshly isolated from heparinized venous blood using 
Ficoll–Hypaque (Sigma–Aldrich, St. Louis, MO) as previously described (12). CD4+ T 
cell and CD14+ monocyte subpopulations were isolated using a magnetic cell sorting 
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system in accordance with the manufacturer’s protocol (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Isolated cells were purified by > 90 % as measured by flow 
cytometric analysis using FACSCalibur TM flow cytometer (BD Biosciences, San Jose, 
CA). To assess the expression of TLRs on monocytes, PBMCs were incubated with 
phosphatidylethanolamine (PE)-labeled anti-TLR2, TLR3, or TLR4 (eBioscience, San 
Diego, CA) and fluorescein isothiocyanate (FITC)-labeled anti-CD14 antibodies (BD 
Biosciences) and analyzed by flow cytometry. Data were analyzed using CELLQuestTM 
Software (BD Biosciences).  
 
Quantitative real-time detection PCR (RTD-PCR). 
RTD-PCR was performed as previously described (15). Briefly, total RNA 
obtained from cells using a MicroRNA isolation kit (Stratagene, La Jolla, CA) was 
reverse-transcribed using 1 μg oligo (dT) primer and Super Script II Reverse 
transcriptase (Invitrogen, Carlsbad, CA). The relative quantities of mRNA expression 
were analyzed by RTD-PCR using ABI PRISM 7900 HT Sequence Detection System 
(Applied Biosystems, Foster City, CA). All primer pairs and probes were obtained from 
the TaqMan assay reagents library. Expression levels of genes were calculated with the 




Apoptotic cell detection assay. 
Freshly isolated PBMCs were incubated with AIM-V (Invitrogen) serum-free 
culture media containing 5 or 30 mM glucose at 37°C with 5% CO2 for up to 24 h. The 
cells were incubated with FITC-labeled anti-CD4, CD14, or CD56 antibodies (BD 
Biosciences) and with PE-labeled Annexin-V and 7-amino-actinomycin D (7-AAD) 
(BD Biosciences) in PBS containing 2% BSA (Sigma–Aldrich). Apoptotic cells were 
determined by flow cytometry as the fraction of cells labeled with Annexin-V that were 
7-AAD negative. At least 10,000 cells per sample were analyzed.  
 
Phagocytosis assay. 
Phagocytotic activity was assessed using Phagotest Kit (Orpegen Pharma, 
Heidelberg, Germany) and FITC-labeled opsonized E. coli in accordance with 
manufacturer’s protocol. Briefly, heparinized whole blood obtained from the 33 patients 
with diabetes and 28 healthy volunteers was incubated with FITC-labeled E. coli for 10 
min at 37°C. After removing the erythrocytes, the remaining cells were incubated with 
propidium iodide to detect viable leukocytes by flow cytometry. Monocyte populations 
were assessed based on cellular granularity and size as side scatter and forward scatter, 
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respectively, and FITC-positive cells were assessed as monocytes with phagocytosed 
FITC-labeled E. coli.  
  
TLR ligand stimuli and expression of pro-inflammatory cytokine genes. 
Peptidoglycan (PGN) (1 μg/ml) from Streptomyces sp. (Sigma–Aldrich), Poly 
(I:C) (5 μg/ml) (Sigma–Aldrich), and Lipopolysaccharide (LPS) (2 μg/ml) from E. coli 
(Sigma–Aldrich), which are TLR2, TLR3, and TLR4 ligands, respectively, were added 
to monocytes (3 × 105cells) freshly isolated from the 33 patients and 28 healthy 
volunteers in AIM-V media. Before and 3 h after incubation, the expression of tumor 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) was analyzed by RTD-PCR.  
 
Analysis of gene expression by DNA microarray. 
Total RNA was obtained from CD14+ monocytes using MicroRNA isolation 
kit (Stratagene, La Jolla, CA), and the mRNA was amplified twice using the 
Amino-allyl MessageAmp aRNA Kit (Ambion, Austin, TX). The reference RNA 
sample was isolated from CD14+ monocytes from a 30-year-old healthy male volunteer 
and amplified in the same manner. Amplified mRNA was labeled with Cyanine (Cy) 5 
or Cy3 (Amersham, Buckinghamshire, UK). Equal amounts of the amplified mRNAs 
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were hybridized to an oligo-DNA chip (AceGene®Human Oligo Chip 30K; Hitachi 
Software Engineering Co., Yokohama, Japan) overnight and washed prior to image 
scanning.   
The fluorescence intensity of each spot on the oligo-DNA chip was obtained 
using cDNA Microarray Scan Array G (PerkinElmer, Wellesley, MA). The obtained 
images were quantified using DNAsis array v2.6 software (Hitachi Software 
Engineering Co.). For normalization, the intensity of each spot with oligo DNA was 
subtracted from that of spots without oligo DNA in the same block. The spot was 
validated when the intensity was within the intensity plus or minus a 2-fold range of 
standard deviation within each block. By calibrating the median as the base value, the 
intensities of all spots were adjusted for normalization between Cy5 and Cy3. 
Hierarchical clustering of gene expression was calibrated using the method described 
above using BRB Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). The 
non-filtered data were log-transformed and applied to the average linkage clustering 
with centered correlation. For the functional analysis of the 813 upregulated genes, we 
used GenMAPP (http://www.genmapp.org), a computer program designed for viewing 
and analyzing genome-scale data on MAPPs representing biological pathways and any 
other groups of genes. 
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 Electron microscopy. 
Monocytes obtained from 3 healthy volunteers and 3 patients with diabetes 
were fixed with 2.5% glutaraldehyde, and then post-fixed in 1% (v/v) 
cacodylate-buffered osmium tetroxide. Samples were dehydrated in a graded series of 
ethanol, transferred to propylene oxide, and embedded in Epon-Araldite. Ultrathin 
sections were obtained and observed under a Hitachi H-7500 electron microscope 
(Hitachi High-Technologies Co., Hitachinaka, Japan). 
 
Caspase-3 assay and enzyme-linked immunosorbent assay (ELISA) of cytokines. 
Monocytes from a healthy volunteer were harvested and treated with 
tunicamycin (1 or 5 μg/ml) in AIM-V media. Every 3 h up to 12 h after tunicamycin 
treatment, we assessed apoptosis by flow cytometry as described above. After 12 h of 
incubation, the expression levels of BCL-2, C/EBP homologous protein (CHOP) and 
(immunoglobulin heavy chain binding protein) BiP were assessed by RTD-PCR. The 
DEVD-cleaving activity of active caspase-3 was measured using labeled 
Asp-Glu-Val-Asp-p-nitroanilide (DEVD-pNA) as the substrate and the Caspase-3 
Colorimetric Assay Kit (Promega, Madison, WI) in accordance with manufacturer’s 
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protocol. The pNA light emission was quantified using a microtiter plate reader at a 
wavelength of 405 nm. In addition, we measured the production of pro-inflammatory 
cytokines by RTD-PCR 6 h after treatment of monocytes (3 × 105 cells) with 
tunicamycin (1 or 5 μg/ml) or the TLR ligands PGN (1 μg/ml), Poly (I:C) (5 μg/ml), 
and LPS (2 μg/ml). The concentrations of TNF-α, IL-1β, and IL-6 in the culture 
supernatants were measured using ELISA kit (eBioscience). 
 
Statistical analysis. 
Data are expressed as means ± SEM. The Mann–Whitney U test was applied to 
assess the significant differences between the two groups. Statistical significance was 











Increased apoptosis of CD14+ monocytes from patients with diabetes  
 We first assessed the frequency of apoptosis in the PBMC fractions from 33 
patients with diabetes and 28 non-diabetic, healthy volunteers. Apoptosis of the isolated 
cells was assessed after 3 h incubation in AIM-V serum-free media containing 5 mM 
glucose (physiological concentration in blood). As shown in Fig. 1A, a significant 
difference in the frequency of apoptosis was observed in the PBMCs isolated from 
patients with diabetes and healthy volunteers. Adding serum to AIM-V serum-free 
media did not affect the difference in apoptosis (data not shown). The numbers of whole 
PBMCs, CD4+, CD14+, and CD56+ cells were similar in both diabetic and healthy 
subjects (data not shown). CD14+ monocytes were observed to be the major contributor 
to the increased apoptosis measured in the PBMCs. In contrast, apoptosis of CD4+ T 
cells and CD56+ NK cells were not significantly different between the two groups (Fig. 
1A). When the incubation period in culture media with or without serum was extended 
to 24 h, about 20% of the CD56+ NK cells of both patients with diabetes and healthy 
volunteers were induced to undergo apoptosis. When incubation period was extended to 
5 days, about 5% of CD4+ T cells of both patients with diabetes and healthy volunteers 
were induced to undergo apoptosis; there was no significant difference in cell viability 
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of CD56+ NK cells and CD4+ T cells between the two groups (data not shown). BCL-2 
expression of CD4+ T cells was not different between the two groups (data not shown). 
Apoptosis of PBMC subpopulations incubated in culture media containing 30 mM 
glucose was not different from cells incubated in 5 mM glucose-containing media (data 
not shown). Moreover, the susceptibility of PBMCs from patients with diabetes to 
apoptosis was not related to clinical features such as vascular complications, insulin 
treatment, and FPG concentrations (data not shown).  
However, among the 33 patients with diabetes, the frequency of apoptotic 
CD14+ monocytes from those with poor glycemic control (HbA1c ≥ 9.0) was elevated 
compared to patients with fair glycemic control (HbA1c < 9.0) (Fig. 1B). Furthermore, 
after 3 h incubation, the increased ratio of the expression of the anti-apoptotic gene, 
BCL-2, was substantially lower in monocytes from the 15 patients with HbA1c ≥ 9.0 
compared to the 18 patients having HbA1c < 9.0, as assessed by RTD-PCR (Fig. 1C). 
These data suggest that the monocytes of patients with diabetes are susceptible to 
apoptosis, especially under conditions of poor glycemic control.  
  
Attenuated function of monocytes from patients with diabetes 
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 To determine if functional alterations exist in monocytes isolated from the 33 
patients with diabetes, we cocultured the monocytes with FITC-labeled E. coli and 
counted the number of fluorescent monocytes indigeting the labeled E. coli by flow 
cytometry. The ratio of monocytes that phagocytosed E. coli to all monocytes in 
patients with diabetes was higher than in the healthy volunteers (Fig. 2A and B). No 
significant correlation was observed between the ratio of phagocytosed E. coli and 
HbA1c levels among the patients (data not shown). 
Next, we assessed the responsiveness of monocytes to external pathogenic 
stimuli in vitro. Monocytes typically express pattern-recognition molecules such as the 
TLRs that are important for innate immunity against various pathogens (13, 14). The 
expression levels of TLR2, TLR3, and TLR4 were not significantly different between 
monocytes from patients with diabetes and those from healthy volunteers, as assessed 
by RTD-PCR (Fig. 3A) and flow cytometry (data not shown). We also found that 
transcriptional expression of TLR signal molecules (MyD88, IRAK1, and TRAF6 for 
TLR2 and TLR4 signaling and TRIF for TLR3 signaling) was not altered in diabetic 
monocytes compared to non-diabetic monocytes (data not shown). Next, we exposed 
the monocytes from the patients with diabetes and healthy volunteers to the TLR 
ligands, PGN (a TLR2 ligand), Poly (I:C) (a TLR3 ligand), and LPS (a TLR4 ligand) 
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and measured the expression of the pro-inflammatory cytokine genes, TNF-α and IL-1β. 
After incubation, the expression of the cytokines was not significantly different between 
the groups (Fig. 3B), but the responsiveness to PGN, Poly (I:C), and LPS was 
significantly attenuated in monocytes from patients with diabetes compared to those 
from healthy volunteers as assessed by RTD-PCR (Fig. 3C and D). These results 
demonstrate that the monocytes of patients with diabetes are functionally impaired, 
which implies that they could contribute to immune deficiency in diabetes. 
 
ER stress is a molecular feature of impaired monocytes 
To elucidate the molecular features of the diabetic monocytes that were 
distinctly susceptible to apoptosis, DNA microarray analysis was performed on CD14+ 
cells isolated from five randomly selected patients with diabetes and five healthy 
volunteers. These subjects demonstrated clinical features near the median of all study 
subjects. Unsupervised hierarchical clustering analysis was performed to assess the gene 
expression profiles of monocytes obtained from patients with diabetes and healthy 
volunteers; 17,184 filtered genes were evaluated after excluding genes that were not 
expressed or those with low expression levels that prevented their analysis in 50 % of 
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the cases. As shown in Fig. 4A, two completely discernible clusters formed between the 
patients with diabetes and the healthy volunteers. 
 We identified 813 genes that were up-regulated in the monocytes from patients 
with diabetes compared to those of healthy volunteers (P < 0.05, student’s t test). 
Analysis of the biological processes concerning these genes was performed using 
GenMAPP. The identified genes were shown to be involved in posttranslational protein 
modification systems occurring in the Golgi-apparatus or were involved in ER stress 
(Table 2, Supplemental Table 1). The elevated expression of genes related to ER stress, 
such as CHOP and BiP, was confirmed using RTD-PCR; the expression of these genes 
was significantly higher in the monocytes from the 33 patients with diabetes than in 
those from the 28 healthy volunteers (Fig. 4B). In contrast, no significant difference in 
the expression of these genes was observed in CD4+ T cells from patients with diabetes 
and healthy volunteers (Fig. 4C). 
 Electron microscopy further confirmed ER stress in the monocytes derived 
from patients with diabetes. As shown in Fig. 4D, morphological alterations of the ER 
such as corruption of concentric, continuous and regular layer structure and a decreased 
number of ribosomes on the ER membrane were evident from the electron 
photomicrographic images.  
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 ER stress-induced apoptosis and attenuation of TLR signaling in human 
monocytes 
The results described above indicated that the monocytes from patients with 
diabetes have compromised immunological function and that ER stress is a distinct 
feature in these cells. To determine whether ER stress could be a mechanism underlying 
the observed increase in apoptosis and decreased responsiveness to TLR ligands, CD14+ 
cells isolated from a healthy volunteer were treated with the ER stress inducer, 
tunicamycin (1 μg/ml), in AIM-V media. As shown in Fig. 5A and B an increased 
number of apoptotic cells was observed among monocytes treated with tunicamycin 
compared to untreated monocytes after more than 6 h incubation. Treatment of 
monocytes with a higher concentration of tunicamycin (5 μg/ml) induced more 
apoptosis (Fig. 5A and B), and when monocytes were treated with tunicamycin for 12 h, 
the activity of the pro-apoptotic protease, caspase-3, significantly increased (Fig. 5C). 
Treatment with tunicamycin coordinately decreased the expression of BCL-2 (Fig. 5D) 
and increased the expression of the ER stress markers, CHOP and BiP (Fig. 5E). These 
results suggest that ER stress promotes apoptosis of human monocytes.  
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     Next, we investigated how tunicamycin-induced ER stress affected the 
responsiveness of human monocytes to TLR ligands. Treatment of monocytes with 
tunicamycin for 6 h did not affect the transcriptional and translational expression of 
TLR2 and TLR4 (data not shown). As shown in Fig. 6A–C, however, the expression of 
the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 were down-regulated after 
stimulation with TLR2 and TLR4 ligands. Furthermore, the production of TNF-α, IL-1β, 
and IL-6 in media was measured by ELISA and found to decrease after treatment of 
human monocytes with tunicamycin and after stimulation with TLR2 or TLR4 ligands 
(Fig. 6D–F). However, tunicamycin-induced ER stress did not affect these expression 












In the present study, we observed that PBMCs from patients with diabetes were 
more susceptible to apoptosis compared to PBMCs from healthy volunteers and that 
CD14+ monocytes comprised the primary PBMC subpopulation undergoing apoptosis. 
We also found that CD14+ monocytes from patients with diabetes were hypo-responsive 
to TLR ligands and that they had attenuated phagocytotic activity. Transcriptional 
analysis and electron microscopy revealed the presence of ER stress in the affected 
diabetic monocytes. Consistently, monocytes isolated from non-diabetic patients 
showed a similar increase in apoptosis and a weakened response to TLR ligands, when 
they were treated with tunicamycin, indicating that ER stress may be a pivotal 
mechanism underlying the decreased immunological function observed in patients with 
diabetes.  
As innate immune-defense mediators, monocytes are capable of ingesting 
exogenous pathogens to protect the host from infectious diseases. Previous studies have 
shown that phagocytosis in diabetic neutrophils and monocytes is attenuated (10, 11). 
Similarly, in our study population, monocytes from patients with diabetes were less 
capable of phagocytosing E. coli pathogens compared to monocytes derived from 
healthy volunteers. This novel finding might explain, at least in part, the decrease in 
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immune function characteristic of patients with diabetes (16). Nevertheless, the detailed 
mechanisms underlying diabetes-induced decreases in phagocytotic activity remain 
unclear, since simple high glucose concentration did neither affect the phagocytotic 
activity and TLR expression, nor induce ER stress in non-diabetic monocytes in vitro 
(data not shown). 
 The TLRs are pattern recognition receptors that are important for recognizing 
pathogens, inducing pro-inflammatory responses, and preventing the host from 
acquiring infectious diseases (17–20). The expression of TLR2, TLR3, and TLR4 in 
CD14+ monocytes was similar between patients with diabetes and healthy volunteers. 
The administration of a high dose of insulin downregulates TLRs expression (21). 
Transformed monocyte-lineage blastoma cells showed increased TLR expression under 
hyperglycemic conditions in vitro (22). Type 2 diabetes is characterized as a state of 
inadequately controlled glycemia associated with hyperinsulinemia due to peripheral 
insulin resistance (1). Taken together, the TLRs expression may be affected by 
hyperglycemia and hyperinsulinemia in a complex manner. In contrast to the previous 
finding that monocytes from patients with diabetes were hypersensitive to the TLR 
ligand, LPS (23, 24), we observed that the TNF-α and IL-1β expression from monocytes 
derived from patients with type 2 diabetes diminished after exposure to PGN, Poly I:C, 
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and LPS—ligands of the TLR2, TLR3, and TLR4 receptors, respectively. These data 
suggest that diabetes perturbs signaling downstream of the TLRs. In this study, we 
collected CD14+ monocytes from PBMCs via enrichment using magnetic beads; this 
protocol was used to remove T cells, NK cells, B cells, dendritic cells, and basophils 
from the PBMC mixture. This is in contrast to the methodology used to isolate these 
cells in many other studies, in which monocytes were obtained as adherent cells in the 
culture dish or by a rosetting technique (25, 26). CD14+ cells have been shown to be 
composed of multiple subtypes of activated states; the classical monocyte-isolation 
methods used in the other studies might unknowingly remove the fraction of monocytes 
that are susceptible to apoptosis (27). Over half of the CD14+ diabetic monocytes 
isolated in this study were dead for 12 h culture even in media containing physiological 
concentration of glucose (data not shown). Our current data showing attenuation of TLR 
responsiveness to ligands in diabetic monocytes suggests that initial immune responses 
that are normally triggered by viruses, bacteria, and parasites could be impaired in 
diabetes, which is consistent with epidemiological data showing a high incidence of 
infection in patients with diabetes (3–5). 
Gene expression and electron microscopic analysis of monocytes derived from 
patients with diabetes showed active signatures of ER stress; this is important because 
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ER is an organelle essential for the proper folding and glycosylation of proteins after 
protein synthesis (28). When cells are under ER stress, protein kinase R-like ER kinase, 
inositol requiring enzyme 1, and activating transcription factor 6 are activated and 
function in the adaptation to stress, proper folding of proteins, and removal of harmful 
unfolded proteins, respectively (29, 30). However, prolonged ER stress leads to 
apoptotic cell death, which is mediated by CHOP (31). CHOP is a crucial and specific 
molecule for ER stress-induced apoptosis and alters the transcription of the BCL-2 gene 
family members (32). The current study showed that diabetic monocytes had increased 
levels of ER stress-related apoptotic molecules. Moreover, non-diabetic monocytes 
treated with tunicamycin, an ER stress inducer, underwent apoptosis in a manner similar 
to monocytes derived from patients with diabetes. From these data, we conclude that ER 
stress contributes to the susceptibility of diabetic monocytes to apoptosis.  
We also observed that tunicamycin-induced ER stress diminished TLR2 and 
TLR4 signaling without altering expression of TLRs. Tunicamycin induces ER stress by 
disturbing N-linked glycosylation (33), and previous reports suggest that perturbations 
in this glycosylation attenuates TLR2 and TLR4 signaling in vitro (34, 35). Hence, 
these data collectively indicate that ER stress may underlie decreases in TLR2 and 
TLR4 signaling and affect immune function in patients with diabetes.  
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TLR3 signaling is different from the other TLR signaling pathway; for example, 
it is independent of MyD88. TLR2 and TLR4 are expressed on the cell surface, whereas 
TLR3 is expressed in intracellular compartments such as endosomes (13), and its 
ligands require internalization before signaling occurs. This suggests that disturbances 
in TLR3 signaling in diabetic monocytes may be due to reasons other than ER stress. 
Further investigations are needed to elucidate the detailed mechanisms of attenuated 
TLR signaling in monocytes from patients with diabetes.  
ER stress has been shown to be a mainstay of the diabetic condition. Its 
pathological importance in diabetes is especially important in pancreatic β-cells, in 
which glucose toxicity results in ER stress and insufficient insulin secretion (36–38). 
The current study suggests that monocytes are yet another population of cells vulnerable 
to hyperglycemia-induced ER stress and dysfunction. Nevertheless, the mechanisms 
that render pancreatic β-cells and monocytes vulnerable to ER stress in patients with 
diabetes remain uncertain. 
Diabetes is considered a chronic inflammatory disease. Activated macrophages 
that produce pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 are thought to 
contribute to insulin resistance in muscle and adipose tissues (39, 40). Furthermore, the 
atherosclerotic complications in patients with diabetes have a basis in inflammation; 
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local inflammatory foci in atherosclerotic lesions are commonly composed of foam cells 
derived from activated macrophages (41, 42). Further studies are needed to determine 
whether different subpopulations of monocyte-derived cells, for example, systemically 
circulating and locally residing inflammatory cells, are susceptible to 
hyperglycemia-induced ER stress and dysfunction.  
In conclusion, our findings show that CD14+ monocytes are susceptible to ER 
stress-induced alterations in inflammatory signaling and apoptosis, which may play a 
role in the decreased immune function observed in patients with diabetes. Further 
investigations are needed to discern the mechanisms of diabetes-induced ER stress and 
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Table 1 Characteristics of the study subjects 






Age (years) 62.0±8.6 58.2±10.2 N.S 
Gender (male/female) 15/18 15/13 N.S 
Body mass index 23.5±4.2 23.6±4.8 N.S 
White blood cell counts (/ml） 4800±1700 5600±1900 N.S 
Lymphocytes (%） 23.5±3.5 22.7±2.5 N.S 
Monocytes (%) 5.2±1.6 6.1±2.3 N.S 
Hemoglobin (g/dl) 14.1±1.3 13.6±1.6 N.S 
Total cholesterol (mg/dl)  182±24 180±35 N.S 
Triglyceride (mg/dl) 138±37 163±33 N.S 
FPG (mg/dl) 185±38 86±7.4 <0.001 
HbA1c (%) 9.2±2.0 5.4±0.7 <0.001 
Diabetic complications (+/-) * 19/14 N.A  
Insulin treatment (+/-)  10/23 N.A  
 
Data are expressed as means±SD.   




















Table 2 Biological processes for up-regulated genes in monocytes of diabetic patients 
MAPP Name  Z Score          Permute P 
Golgi-apparatus 3.383 0.000 
Ribosomal Proteins 3.691 0.002 
Unfold protein binding  2.471 0.026 
Intracellular protein transport 2.310 0.029 
Enzyme liked receptor protein signaling pathway 2.175 0.042 
Nuclear Receptor 2.316 0.043 
































Monocytes contributed to the vulnerability of the PBMCs in patients with diabetes. (A)
PBMCs were obtained from 33 patients with diabetes and 28 healthy volunteers. 
Isolated PBMCs were harvested in AIM-V serum-free culture media supplemented with 
5 mM glucose for 3 hours and incubated with FITC-labeled anti-CD4, CD14, or CD56 
antibodies, together with PE-labeled Annexin-V to assess the frequency of apoptotic 
cells in each subpopulation of PBMCs. Apoptotic cells were identified by 
double-staining with PE-labeled Annexin-V and 7-AAD by flow cytometry. The 
frequencies of apoptotic cells determined as the Annexin-V-positive and 
7-AAD-negative population are expressed as mean ± SEM with statistical comparisons 
for both groups. The non-parametric Mann-Whitney U test was used to calculate the P 
value. *P < 0.05 ***P < 0.01 ***P < 0.001. The PBMCs of patients with diabetes 
were more susceptible to apoptosis than those of healthy volunteers, and CD14＋ 
monocytes were contributors. (B) Among the 33 patients with diabetes, those with poor 
glycemic control reflected as HbA1c ≥ 9.0 were more susceptible to apoptosis in CD14＋ 
monocytes. Data are expressed as mean ± SEM with a statistical comparison of both 
groups. *P < 0.05. (C) Monocytes were isolated from 15 patients with HbA1c ≥ 9.0 and 
18 patients with HbA1c < 9.0. The expression of the BCL-2 gene in their monocytes 
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before and after incubation in AIM-V serum-free media was assessed by RTD-PCR. 
After 3 h incubation, the expression of BCL-2 was not upregulated in the poor 
glycemic control group (HbA1c ≥ 9.0), as compared to the fair control group (HbA1c < 




Attenuated phagocytosis activity in diabetic monocytes. Whole PBMCs were incubated 
with FITC-labeled E. coli for 10 minutes followed by PI staining and flow cytometric 
analysis. (A) Gated PI-positive populations were viable leukocyte populations (upper 
panel). The monocyte population was assessed using granularity (SSC) and size (FSC) 
(middle panel). For the gated cells indicating viable monocytes, FITC-positive cells 
were assessed as monocytes containing phagocytosed FITC-labeled E. coli. (lower 
panel). (B) The frequency of monocytes containing phagocytosed E. coli in patients 
with diabetes was less than that in healthy volunteers. Data are expressed as means ± 
SEM. *P < 0.05. 
 
FIG. 3 
Hyporesponsiveness to TLR ligand stimuli by the monocytes of patients with diabetes. 
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(A)-(D) Isolated CD14＋ monocytes from 33 patients with diabetes and 28 healthy 
volunteers were cultured in AIM-V serum-free media supplemented with each TLR 
ligand: PGN, Poly (I:C), and LPS. After 3 h incubation, RNA was isolated from the 
monocytes and the expression levels of the TNF-α and IL-1β genes were analyzed by 
RTD-PCR. The basal (pre-stimuli) expression of (A) TLR2, TLR3, and TLR4 and (B) 
TNF-α and IL-1β did not differ significantly between the two groups. The TLR 
ligand-induced expression of (C) TNF-α and (D) IL-1β was downregulated in the 
monocytes of patients with diabetes. Data are expressed as means ± SEM. *P < 0.05, 
**P < 0.01. 
 
FIG. 4 
Monocytes of patients with diabetes were under ER stress. (A) The gene expression 
profiles of representative vulnerable CD14＋ monocytes obtained from five patients with 
diabetes and five healthy volunteers were analyzed using a DNA microarray. 
Unsupervised hierarchical clustering using 17,184 filtered genes produced two clusters 
that separated the patients with diabetes from the healthy volunteers without exception. 
(B)–(C), The gene expression levels of the ER stress markers, such as CHOP and BiP, 
on CD14＋ monocytes and CD4＋ T cells obtained from 33 patients with diabetes and 28 
healthy volunteers was analyzed using RTD-PCR. (B) The expression levels of CHOP 
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and BiP in monocytes of patients with diabetes were significantly upregulated, as 
compared to the monocytes of healthy volunteers. Data are expressed as means ± SEM. 
*P < 0.05, **P < 0.01. (C) The expression levels of CHOP and BiP in T cells of 
patients with diabetes were similar to those of healthy volunteers. Data are expressed as 
mean ± SEM. (D) Monocytes were obtained from three healthy volunteers and three 
patients with diabetes (Healthy volunteer 1: 64-year-old man, HbA1c 5.7%; Healthy 
volunteer 2: 66-year-old man, HbA1c 4.9%; Healthy volunteer 3: 68-year-old woman, 
HbA1c 5.6%; Diabetic patient 1: 56-year-old man, HbA1c 9.1%; Diabetic patient 2: 
64-year-old woman, HbA1c 8.2%; Diabetic patient 3: 71-year-old man, HbA1c 10.2%) 
and examined them using electron microscopy. In the three patients with diabetes, the 
concentric, continuous, and regular layer structures of the ER were corrupted, with 
fewer ribosomes on the ER membrane compared to the ER of the healthy volunteer. ER, 
endoplasmic reticulum; N, nucleus; M, mitochondrion. Scale bars indicate 100 nm. 
 
FIG. 5 
ER stress enhanced the susceptibility of human monocytes to apoptosis. (A)–(B) 
Human CD14＋ monocytes obtained from a healthy volunteer were incubated in AIM-V 
culture media supplemented with tunicamycin (1 or 5 µg/ml). The frequency of 
apoptotic cells was analyzed by flow cytometry every 3 h for 12 h. More apoptotic cells 
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were observed among monocytes treated with tunicamycin for more than 6 h incubatio
n, as compared to untreated monocytes. (A) Representative scattergram of Annexin-V 
and 7-AAD for monocytes treated with tunicamycin. The numbers in each quadrant 
indicate the percentage of apoptotic cells. (B) Apoptotic cells were assessed in triplicate 
for each condition. Data are expressed as means ± SEM. (C) Caspse-3 activity in 
monocytes treated with tunicamycin increased significantly at 12 h incubation. (D) 
The BCL-2 expression in monocytes incubated with tunicamycin for 12 h was down-
regulated. (E) The expression levels of the ER stress markers CHOP and BiP in 
monocytes incubated with tunicamycin for 12 h were significantly up-regulated. Data 
are expressed as means ± SEM of three independent experiments. Open bars, no 
treatment; shaded bar, treatment with tunicamycin (1 µg/ml); solid bar, treatment with 
tunicamycin (5 µg/ml). TM, tunicamycin. 
 
FIG. 6 
Expression of pro-inflammatory cytokines in response to TLR ligand stimuli decreased 
in human monocytes treated with tunicamycin. Isolated human CD14＋ monocytes were 
incubated in AIM-V culture media with tunicamycin (1 or 5 µg/ml) and stimulated 
using TLR ligands, PGN, and LPS for 6 h. A–C, RTD-PCR analysis showed that the 
expression of TNF-α (A), IL-1β (B), and IL-6 (C) was down-regulated in human CD14＋ 
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monocytes treated with tunicamycin, especially at the higher concentration (5 µg/ml). 
D–F, ELISA showed that the production of TNF-α (D), IL-1β (E), and IL-6 (F) in 
culture media decreased in human monocytes treated with tunicamycin, especially at the 
higher concentration (5 µg/ml). Data are expressed as means ± SEM of four 
independent experiments. Open bars, no treatment; shaded bar, treatment with 
tunicamycin (1 µg/ml); solid bar, treatment with tunicamycin (5 µg/ml). TM, 
tunicamycin. 
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